May 15, 2013

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials

 

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials

Paris, France and Tarrytown, NY – May 15, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.